Physician profile
Jon David Hammer
NPI 1013449388
$2,025.78
in general payments reported to CMS, 2019-2025
13 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $22.98 · 2022: $54.81 · 2023: $763 · 2024: $335 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,549.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $776.67 | 2019-2025 | Hydrus Microstent, Clareon, Rocklatan |
| Glaukos Corporation | $265.33 | 2023-2025 | Idose, Radius |
| Abbvie INC. | $238.07 | 2023-2025 | |
| Mallinckrodt Enterprises LLC | $237.61 | 2019 | |
| Bausch & Lomb Americas INC. | $169.10 | 2023-2025 | Vyzulta, Xiidra |
| Genentech USA, INC. | $120.74 | 2023 | Vabysmo |
| Oyster Point Pharma, INC. | $51.14 | 2023 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $40.37 | 2023-2025 | Tecnis Iol |
| Ocular Therapeutix, INC. | $40.34 | 2024-2025 | Dextenza |
| Novartis Pharmaceuticals Corporation | $34.97 | 2022-2023 | |
| Astellas Pharma US INC | $21.60 | 2025 | Izervay |
| Dompe US, INC. | $15.82 | 2025 | Oxervate |
| Harrow Eye, LLC | $14.02 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Hammer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.